A spanner in the works | Opinion – Chemistry World

If you look at the pharmacopeia, the list of drugs we have approved and available, all the way from the early plant-derived compounds like digitalis and morphine and up through aspirin and antibiotics to the very latest therapies, you will see drugs targeted at a huge range of diseases. But there is a common feature to the vast majority of known drugs that may not be obvious at first: they generally work by causing something else to fail.

Consider some of the best-populated classes of drug mechanisms, those working through cellular receptor proteins and on enzymes. The clear majority of receptor-based drugs are antagonists, compounds that block the signaling of the receptor and keep it from responding to its natural ligand (either partially or totally). And the overwhelmingly larger set of enzyme-targeting drugs are inhibitors, compounds that work by blocking the enzymes active site one way or another to reduce its activity.

The true direct enzyme activator stories can be counted on fingers

There are exceptions agonist drugs on receptors cause them to respond more strongly or for longer duration than they might otherwise, for example. And theres a whole class of drugs, with insulin leading the list, that simply try to replace a key biomolecule that some patients lack. But most of the time, in most situations, drugs work on a similar principle to that of a well-aimed wrench being thrown into the gears of a complex machine. We are trying to bring some select part of the system to a halt, and a good part of the search for new medicinal chemistry targets consists of finding things whose stoppage might be beneficial.

Put simply, its just easier to interfere with the many pieces of a living organism than it is to directly make them work better. Enzymes, for example, have all had long evolutionary histories that have optimised their activity to extraordinary degrees. The chances, therefore, of making one more selective or faster-acting through the binding of an outside drug molecule are very small indeed. The true direct enzyme activator stories can be counted on fingers. But clogging up an enzymes active site with an extraneous molecule thats hard to dislodge? There you have better chances.

So the art is to find situations where some disease mechanism can be usefully altered by causing some part of it to break down. A target thats doing too much work in a given disease process is an obvious candidate, and you can try to shut these down directly if they have a druggable site. But what about the situations where some activity needs to be increased? If you really do need a key enzyme to work harder, then look for something in the cell that naturally inhibits it, and gum up the process that produces this inhibitor. Or look for the signals that cause your enzyme to become less active or to be broken down and cleared from the cell: there may well be a phosphorylation step that helps to turn its activity off or down, for example. In that case, an inhibitor of the kinase enzyme that adds that particular phosphate group might be just what you need. These sorts of indirect bounce shot mechanisms are widespread.

If you really do need an enzyme to work harder, then look for something that naturally inhibits it, and gum [that] up

One of the hottest areas of current drug research takes this idea even further. Targeted protein degradation hijacks the cells own protein-recycling machinery. Tagging particular proteins with ubiquitin side chains marks them for destruction in the cells proteasome. To get this to work, you have to look through disease mechanisms with an eye to the ones where yanking one particular part out of the cell completely would benefit the patient. An interesting complexity of doing it this way as opposed to finding a small-molecule inhibitor of that same protein is that many proteins have functions that may have nothing to do with their active site (associating with other proteins and altering their activities in turn, for example). Targeted degradation removes all of these, since it removes the whole protein by dropping into the cellular equivalent of a waste disposal shredder, while a standard inhibitor might leave several of a proteins other activities still functional. Sometimes this is a desirable feature, but sometimes it may not be!

That, then, is a key secret of success in drug discovery (well, its earliest stages), and I am passing it on to you free of charge: look for things that you can inhibit, disturb, slow down, or completely destroy. And choose carefully!

Read the original:
A spanner in the works | Opinion - Chemistry World

Pioneering Researcher of Reticular Chemistry and UC Berkeley Professor Dr. Omar Yaghi to Present Shipley Distinguished Lecture at Clarkson University…

Dr. Omar Yaghi

Dr. Omar Yaghi will present two lectures at Clarkson Universitys 26th Shipley Distinguished Lectureship next month. The lectures will be held virtually via Zoom, and are open to the public.

Professor Omar M. Yaghi is a professor of chemistry at UC Berkeley and is widely known for pioneering several extensive classes of new materials: MetalOrganic Frameworks (MOFs), Covalent Organic Frameworks (COFs), and Zeolitic Imidazolate Frameworks (ZIFs). These materials have the highest surface areas known to date, making them useful for hydrogen and methane storage, carbon capture and conversion, water harvesting from desert air, and catalysis, to mention a few. The building block approach he developed has led to an exponential growth in the creation of new materials having diversity and multiplicity previously unknown in chemistry. He termed this field Reticular Chemistry and defines it as stitching molecular building blocks into extended structures by strong bonds. Please visit his webpage to read more about Dr. Yaghi and his research.

Professor Yaghi will offer two virtual lectures. The first one, titled Harvesting Water from Desert Air will be held Thursday, April 7, 2022, at 4:30 pm EDT. Click here to register for the Zoom event. https://clarkson.zoom.us/meeting/register/tJ0qdOyhqDotGNQOVm6CFvdUrTNb-i9uKwFQ

The second virtual lecture, titled RETICULAR CHEMISTRY: The atom, the molecule, and the framework will be held Friday, April 8, 2022, at 3:30 pm EDT. Click here for the Zoom event. https://clarkson.zoom.us/s/91407233738

Yaghi is an elected member of the National Academy of Sciences and has been honored with many awards for his scientific accomplishments, including the Materials Research Society Medal and the American Chemical Society Award in the Chemistry of Materials. He recently became the inaugural recipient of the VinFuture Special Prize which is dedicated to Innovators with Outstanding Achievements in Emerging Fields.

The Shipley Distinguished Lectures are sponsored by the Shipley Family Foundation, with support from Clarksons Center for Advanced Materials Processing (CAMP) and the Department of Chemistry & Biomolecular Science. The lectures were initiated in 1994 by the late Professor Egon Matijevic through a generous gift from the foundation on behalf of the late Lucia and Charles Shipley.

The Universitys relationship with the Shipleys dates to 1970, when Matijevic was invited by the Shipley Company to successfully resolve a patent situation involving their critical catalyst in electroless plating, establishing a professional relationship between the two entrepreneurs that continued for years.

For more than 20 years, distinguished speakers from around the world, including ten Nobel Laureates, have presented talks. The purpose of the lectures is to promote scholarly achievement at Clarkson by providing the opportunity for idea exchange and active learning, as well as allowing undergraduate and graduate students to meet the most prestigious speakers from all over the world.

For more information about the lectures, please contact Elizabeth McCarran at 315-268-6658 or emccarra@clarkson.edu.

Continue reading here:
Pioneering Researcher of Reticular Chemistry and UC Berkeley Professor Dr. Omar Yaghi to Present Shipley Distinguished Lecture at Clarkson University...

AOR-29 Researcher in Electrochemical Nanosensors Development chemistry job with TYNDALL NATIONAL INSTITUTE | 288209 – Times Higher Education

AOR-29 Researcher in Electrochemical Nanosensors Development chemistry

Contract: Full Time/Fixed Term

Tyndall is a core partner in the VistaMilk Centre. The Science Foundation Ireland/Department of Agriculture, Food and the Marine: VistaMilk Centre for innovative Smart precision pasture-based dairying, brings together a number of major Irish research providers to facilitate the development and deployment of new knowledge, new ICT technologies and new decision support tools to maximise the efficiency and effectiveness of the entire dairy production chain. To this end, Vistamilk will develop new, and advance existing, electronic monitoring and sensing technologies to transform an already world-class dairy sector into a global leader in sustainable Agri-Tech and also provide a one-stop-shop for research, education and innovation within this domain. Tyndall is leading the Smart Sensor Systems hardware development. As one of Europe s leading ICT institutes, with over 600 people and a capital infrastructure in excess of 250m, Tyndall is now focusing its research in microelectronics and front end sensor development into making smart things for the Internet of Farm .

Applications are invited for a Post-Doctoral research position within the Nanotechnology Group at the Tyndall National Institute University College Cork. The position is initially for two years with potential for extension pending further funding. We have recently developed new integrated electrochemical nanosensors employing nanowires as sensing elements on-chip and have demonstrated significantly enhanced sensitivity, when compared to the state of the art, for a range of important molecules including: chemical analytes (e.g., pesticides) and biochemicals analytes (e.g., glucose, dopamine). These new sensors have been sufficiently developed to allow electrochemical-based label-free detection of binding events including antibody-antigen. Recently we have shown label-free immunoassays at single nanobands and demonstrated real-time detection (time to detection: 15 minutes) of viruses and antibodies in serum.

Purpose of the role

The candidate will co-develop new approaches for chemical modification of sensors, based on organic/inorganic materials, to confer selectivity for detection of different cationic and ionic species in water and milk. Using an iterative approach, nanoelectrodes will be chemically modified, characterised and optimised for the multiplexed detection of target species. The work will involve the development of state-of-the-art research methods that involve nanosensor development and fabrication (in collaboration with the nano-fabrication facility at Tyndall) chemical modification of gold or platinum nanoelectrodes using additive chemical approaches, test, characterisation, evaluation, integration with electronic circuitry (in collaboration with the microelectronic circuit centre of Ireland at Tyndall) field deployment and validation.

In general, researchers at Tyndall are also expected to participate in the full range of activities of the group, contributing to collaborative projects, particularly where their special expertise can make a direct contribution. MNS plays a leading role in the Science Foundation Ireland / Department of Agriculture Food and the VistaMilk Centre which involves close collaboration with industry as well as national and international academic research groups. The candidate is expected to contribute to these collaborations, in particular helping to generate and deliver industry projects which are mainly in the area of sensor development and system validation and test.

The researcher is expected to have a strong track record of achievement and experience in the field (at least 3 years post PhD) of electrochemical sensor development, including experience of working on industrial projects, although not necessarily in a leading role.

This post is an initial two-year post-doctoral position linked to the funding opportunities of the MNS centre.

Key Duties and Responsibilities

Essential criteria

Desirable criteria

Appointment may be made on the IUA Scale for Post-Doctoral Researchers 39,130- 46,442pa. Salary placement on appointment will be in accordance with public sector pay policy.

Informal enquiries can be made in confidence to Dr. Alan O Riordan at alan.oriordan@tyndall.ie

Application Instructions:

Please click here to applyhttps://www.tyndall.ie/aor-29-researcher-in-electrochemical-nanosensors-development-_-chemistry

Handwritten forms will not be accepted.

Please note that Garda vetting and/or an international police clearance check may form part of the selection process.

The University, at its discretion, may undertake to make an additional appointment(s) from this competition following the conclusion of the process.

At this time, Tyndall National Institute does not require the assistance of recruitment agencies.

Tyndall National Institute at University College, Cork is an Equal Opportunities Employer.

Continue reading here:
AOR-29 Researcher in Electrochemical Nanosensors Development chemistry job with TYNDALL NATIONAL INSTITUTE | 288209 - Times Higher Education

Sea sponges own unique chemistry goes beyond that of their bacterial guests – Chemistry World

Sea sponges, simple animals that fossil evidence shows have been around for about 1.8 billion years, are teeming with unique chemistry. Up until now researchers assumed most of the really interesting chemistry was being carried out by their symbiotic bacteria, but now theyve discovered that the sponges can produce biologically active compounds that could be drug candidates.

The new work was carried out by Bradley Moores marine chemistry and geochemistry lab at the University of California, San Diegos Scripps Institution of Oceanography in the US and presented at the American Chemical Societys spring conference held virtually and in-person in San Diego.

A genetic analysis conducted by Kayla Wilson, a PhD student in Moores lab, found that a range of unusual nitrogen-containing terpenes produced by the sea sponge Axinella are actually made by the sponge and not its microbes. To study the genetic sequences responsible for making these compounds, Wilson sequenced the sponges DNA and that of its microbiome to determine which genes produced the terpenes. To do that she searched for sequences encoding terpene synthase an enzyme responsible for a key step in terpene production. Together with a colleague who had studied the same enzyme in corals, she concluded that the compounds came from the sponge itself.

Moore says that discovering sponges can make these compounds themselves represents a fundamental shift in the field. If this animal is making this funky little terpene, what else are animals making? he asks. I think this opens the door to a new emphasis on animals as vessels for drug discovery.

Paco Cardenas, a sea sponge expert at Uppsala University in Sweden who was not involved in this work, confirms that terpenes are usually produced by plants so it is unusual that these animals are making them. It is surprising, and it is a nice discovery, but we already know that sponges themselves can produce other types of chemistry such as sterols, like cholesterol, and peptides, he adds, noting that sea sponges produce the highest diversity of sterols of any animal on Earth, and they make these themselves.

It would be even more exciting if similar compounds are identified that have significant biological activity against bacteria or cancer cells, and they too are determined to be made by sea sponges, Cardenas says. We could then produce substantial amounts of these compounds, and we could move to sponge culture where you take pieces of sponge and let them grow in a seawater aquarium and then cut them again until you get enough biomass to extract your compound of interest, he tells Chemistry World.

Vikram Shende, a postdoc in Moores lab also discussed his discovery of new compounds from the local Cliona sea sponge at the ACS meeting. Shende and two undergraduate students extracted compounds from 13 species of sponge, and after testing the extracts for biological activity they identified bromine-containing peptides which were shown to inhibit bacteria growth.

Shende and his colleagues are now trying to determine the molecular structure of these peptides, and whether they have potential as an antibiotic. The researchers have yet to determine if these brominated compounds are made by these sponges or the microbes within them.

Compounds with bromides are very common with sponges and marine organisms in general, and bromide on peptides has been found but is less common, Cardenas points out. If this is a really big peptide then that is quite rare, but there are not many details provided.

Shende argues that this research and research at Moores lab demonstrates why local biodiversity is so crucial. I really want people to take away that it is important to preserve local biodiversity, not only because of environmental reasons but because we have this incredible treasure trove of molecules that might end up making life-saving medicines, he said.

Continue reading here:
Sea sponges own unique chemistry goes beyond that of their bacterial guests - Chemistry World

Lee Joon Gi Shows All Kinds Of Chemistry With Kim Jae Kyung, Lee Soon Jae, And More In Again My Life – soompi

SBS has shared new stills from its upcoming drama Again My Life!

Again My Life is a drama about a young prosecutor who gets a second chance at justice after failing to bring down a powerful person.Lee Joon Gistars as Kim Hee Woo, who was unjustly killed while investigating a corrupt politician but unexpectedly gets a second chance at life.Kim Ji Eunstars as Kim Hee Ah, a genius and the youngest daughter of Cheonha Groups CEO.

As Kim Hee Woo gears up for revenge in his second shot at life, he will partner up with many people includingLee Min Soo (Jung Sang Hoon),Kim Han Mi (Kim Jae Kyung),Kim Gyu Ri (Hong Bi Ra), and Woo Yong Soo (Lee Soon Jae).

In the newly released photos, Kim Hee Woo shows various kinds of chemistry with his allies. In one photo, thesociable and popular Lee Min Soo approaches Kim Hee Woo, his junior colleague, first.The two are completely different from each other, but later on, they become close friends.

Kim Hee Woo will also have intriguing chemistry with Kim Han Mi and Kim Gyu Ri, whose lives have changed because of him. Kim Han Mi is a journalist whose status as a child born out of wedlock led her to spend her grade school years with a twisted view of the world, while Kim Gyu Ri is a prosecutor who went to the same high school as him. Both will join him on his quest for justice.

Another helpful aid is Woo Yong Soo, a real estate expert. Kim Hee Woo needs financial power to get revenge againstJo Tae Sub (Lee Kyung Young), and he will meet Woo Yong Soo who can show him the way. The two characters will show perfect pupil-teacher teamwork.

Again My Life premieres on April 8 at 10 p.m. KST and will be available with subtitles on Viki!

Watch a teaserfor the drama with English subtitles below:

Watch Now

Source (1)

How does this article make you feel?

Excerpt from:
Lee Joon Gi Shows All Kinds Of Chemistry With Kim Jae Kyung, Lee Soon Jae, And More In Again My Life - soompi

Turning off the plastic tap | Opinion – Chemistry World

A historic agreement has been reached on plastic pollution. 175 nations that met in Nairobi, Kenya, in March have agreed to come up with a binding treaty to tackle a problem that no one nation can address on its own. But how big is the problem of plastic pollution?

The figures for plastic waste are shocking. Seventy years ago production was relatively low, with 2 million tonnes of plastic produced in 1950. Today production is pushing towards 350 million tonnes per year and much of it is going into packaging, textiles and consumer goods that we all use. Yet despite recycling rates increasing to a little over 20%, the majority of that plastic (55%) is discarded with the remainder incinerated. The world isnt coping well with that 55% it discards either. Models suggest that about 11 million tonnes of it is entering the worlds oceans every year and three-quarters of the plastic ever made is now waste.

The United Nations Environment Programmes (UNEP) draft resolution concedes that theres no one solution to the problem. To be sure, organised waste management collection systems will play a part. UNEP also goes out of its way to highlight that the informal waste management economy waste pickers will be important where state-run waste systems are inadequate. A significant reduction in plastic production is also desirable. Recycling and a circular economy are also on UNEPs wish list, and this is where the chemical industry and chemists can shine.

There are clearly opportunities for conventional recycling technologies to reform graded plastics into new items. However, this tends to lead to a lower quality product than those made with virgin petrochemicals. The dream solution to the plastics that the world cant do without would be depolymerisation technologies that can break polymers down into their constituent monomers cheaply and simply, which is why it features in our pages so often. A challenging task, but one that chemists are already rising to.

The next two to three years will be where the hard work really starts for negotiators from these countries. Getting 175 countries to agree on a wide range of binding measures to reduce, reuse and recycle plastics will be difficult. The excellent news is that they will be guided by top scientists sitting on a new international advisory panel that is being set up now and which is modelled on the Intergovernmental Panel on Climate Change. The first step has been taken and its time for chemistry to play its part in solving a problem that it has helped to create.

See the article here:
Turning off the plastic tap | Opinion - Chemistry World

Schultz: On changes, chemistry and the Braves’ belief they have what it takes to win it all again – The Athletic

NORTH PORT Chemistry, according to Merriam-Webster, is the interaction between people working together, specifically such interaction when harmonious or effective. It should be noted that both Merriam and Webster were book publishers and clearly very into dictionaries, not trash novels, so Im going to assume here that neither was much fun at parties or played a lot of sports, and therefore they would have no feel whatsoever as to how chemistry often impacts whether a team wins or loses.

So lets start with this summation on the importance of chemistry in a baseball clubhouse from Adam Duvall, a former All-Star, who is entering his ninth season in the major leagues with four franchises and has experienced a World Series title and 90-plus-loss seasons.

Its probably overlooked more than it should be, the Braves outfielder said. Its such a long season thats why its so important. Youre spending so much time together. It makes it easier and more fun when guys can come in and be in a good mood and just be able to pull on the same side of the rope.

Theres an ongoing debate about how much impact the loss of Freddie Freeman will have on Atlanta. Offensive production is tangible and easily measured. Harder to define is what most dont see behind the scenes: players seeing a teammate gut it out with injuries to play every day; telling a player whos on the training table his team needs him that day and he needs to play; having the status and presence to command respect to lead an important team meeting during a slump.

Excerpt from:
Schultz: On changes, chemistry and the Braves' belief they have what it takes to win it all again - The Athletic

Integrating Physics, Chemistry, Biology and Medicine to Optimize Radiopharmaceutical Therapy – Argonne National Laboratory

Abstract: Radiopharmaceutical therapy poses a unique set of opportunities and challenges. This is the only form of radiation therapy that can target cancer cells precisely at the cellular level, a key requirement for eliminating circulating tumor cells, disseminated tumor cells, and oligometastases. Yet this distinct advantage over other radiation therapies also poses challenges for harnessing its power and for developing predictive dose response relationships. Each radionuclide (and daughter radionuclide) emits a unique set of radiations with different linear energy transfer and ranges in tissue. These can include Auger electrons, conversion electrons, particles, x rays, rays, and particles. The relative biological effectiveness (RBE) of these radiations can depend on the subcellular distribution of the radionuclide in the tissue of interest and on radiation dose rate patterns that are dictated principally by radiopharmacokinetics and the range of the emitted radiations. Recent advances have improved our capacity to develop predictive dose response relationships and harness the power of radiopharmaceutical therapy. Among the advancements that will be discussed are the importance of activity distributions, dose rate patterns, and RBE. Recognizing that distribution of the radiopharmaceutical at the cellular level trumps RBE of the radiations emitted, novel approaches to distribute the dose more uniformly over the targeted cell population will also be discussed. Finally, the role of radiation-induced bystander effects in radiopharmaceutical therapy will also be discussed.

Original post:
Integrating Physics, Chemistry, Biology and Medicine to Optimize Radiopharmaceutical Therapy - Argonne National Laboratory

Louisiana chemical production outlook best weve seen in several years – Greater Baton Rouge Business Report

Louisianas chemical manufacturing sector could be poised for a booming year, says Rhoman Hardy, senior vice president, U.S. Gulf Coast, Shell Chemicals and Products.

Louisianas industry will benefit from low natural gas prices and rising demand for vehicles and homes and is well-positioned for the transition to a lower-carbon, more sustainable future, according to participants in a webinar hosted today by 10/12 Industry Report and Business Report. But their optimism was tempered by concerns about inflation and companies supply chains.

Our outlook for chemical production is really the best weve seen in several years, says Martha Gilchrist Moore, chief economist with the American Chemistry Council.

Meeting the industrys customer demands for a lower carbon footprint will require emphasizing efficiency and renewable energy while scaling up existing technologies and developing new ones, says David Yankovitz, chemical practice leader with Deloitte. He says some companies have set up supply chain war rooms focused on the three main challenges: supply shortages, labor availability, and transportation and logistics.

According to the speakers:

Go here to see the original:
Louisiana chemical production outlook best weve seen in several years - Greater Baton Rouge Business Report

‘Death on the Nile’ Exclusive Clip: Inspector Poirot Feels Strong Chemistry With Alluring Character in Deleted Scene – PopCulture.com

Each product has been independently selected by our editorial team. We may receive commissions from some links to products on this page. Promotions are subject to availability and retailer terms.

Death on the Nile is now available to buy from online retailers in 4K UHD, Blu-ray and DVD, and PopCulture.com has an exclusive deleted scene from the thrilling mystery film. In the clip, we see more of the chemistry between Inspector Hercule Poirot (Kenneth Branagh) and jazz singer Salome Otterbourne (Sophie Okonedo). The pair runs into one another in an Egyptian marketplace, and spend time discussing Salome's niece/business manager, Rosalie (Letitia Wright) and Jacqueline "Jackie" de Bellefort (Emma Mackey).

The deleted scene offers viewers a deeper insight into the dynamic between Poirot and Salome, with whom the inspector is smitten. At the beginning of the film we find him watching her perform in a London nightclub. Later, the pair end up on the same honeymoon trip for wealthy heiress Linnet Ridgeway-Doyle (Gal Gadot) and Simon Doyle (Armie Hammer). Notably, Poirot had previously noticed Simon with Jackie weeks back while at the London jazz club.

Death on the Nile is a sequel to Murder on the Orient Express (2017) and is based on the renowned 1937 Agatha Christie novel of the same name. The film follows Poirot as he attempts to uncover a murder mystery aboard the S.S. Karnak cruise ship while it floats down the Nile river. The film was directed by Branagh, from a screenplay byMichael Green. Additional cast members include Annette Bening, Russell Brand, Ali Fazal, Dawn French, Rose Leslie, and Jennifer Saunders.

In a previous interview with Stack, Branagh opened up about why he wanted to return to the role of Inspector Poirot. "I guess we are trying to deepen what we did with Murder on the Orient Express and go produce this entertaining mystery with this incredible group of actors and delve into a dangerous love triangle, which involves this friendship circle. It invites you to work out who do you love and who do you hate and who do you desire?"

Commenting on assessments that the story is one of Christie's most personal, the filmmaker offered, "Yeah, it feels personal and heartfelt. I think that she had her own share of heartache to do with love. So I think all the characters have a relationship to love and to lust. The hunger for sex in Agatha Christie's original story is very powerful, and people are reckless in their pursuit of it. Their greed for physical satisfaction is dangerous to a murderous degree." Death on the Nileis available now to own on Digital retailers such as Prime Video, Vudu/Fandango and Apple, and on 4K Ultra HD, Blu-ray & DVD April 5th.

Link:
'Death on the Nile' Exclusive Clip: Inspector Poirot Feels Strong Chemistry With Alluring Character in Deleted Scene - PopCulture.com

Neurology specialist addresses aphasia, the illness affecting Bruce Willis – University of Miami: News@theU

Dr. James Galvin, chief of the Division of Cognitive Neurology at the University of Miami Miller School of Medicine, explains the brain disorder afflicting Bruce Willis that has caused him to step away from his acting career.

The entertainment world was shocked Wednesday when Bruce Willis and his ex-wife Demi Moore announced that the Hollywood icon of the Die Hard movie franchise is suffering from aphasia.

Around the world, many people Googled the word to learn what it meant and what the diagnosis would entail for the popular actor moving forward. In a statement on her Instagram account, Moore addressed Willis amazing fans to share that his cognitive abilities have been impacted.

As a result of this and with much consideration, Bruce is stepping away from the career that has meant so much to him, Moore said. This is a really challenging time for our family, and we are so appreciative of your continued love, compassion, and support. The post is signed by Willis current wife Emma, Moore, and his children Rumer, Scout, Tallulah, Mabel, and Evelyn.

Willis, 67, is a Hollywood superstar who has starred in dozens of critically acclaimed films including, Pulp Fiction, The Sixth Sense, and the Die Hard series. According to The New York Times, Willis has received three Golden Globe nominations, capturing one. He also won an Emmy for outstanding lead actor in a drama series for the TV show Moonlighting.

Dr. James Galvin, a professor of neurology at the University of Miami Miller School of Medicine and chief of the Division of Cognitive Neurology, explains aphasia and its treatment.

What is aphasia?

Aphasia is a medical term to describe conditions of disturbance of language (speaking, writing, reading, and comprehension) and is due to damage to the language centers in the brain. Aphasia can be fluent with good production of words, but a loss of the comprehension and understanding of the meaning of the words produced, or non-fluent with relatively preserved comprehension but a great difficulty in language expression such as speaking or writing. The illness can be caused by a focal injury such as a stroke, traumatic injury, or brain infection (encephalitis). In this case, the presentation of aphasia is typically mire acute or sudden. Aphasia can also be caused by more slowly progressing processes such as a brain tumor or a neurodegenerative disease such as Alzheimers disease or frontotemporal degeneration. In particular, a type of frontotemporal degeneration is known as primary progressive aphasia where language problems are the first, and in many cases the only symptoms.

Who is most at risk of contracting this disease?

This depends somewhat on the underlying cause. In the case of a neurodegenerative disease, older age is a strong risk factor. Frontotemporal degeneration, for example, typically begins sometime between the late 40s to mid-60s, while Alzheimers disease more commonly begins at a later age.Tumors and strokes can occur at any age but are more common with increasing age.

Is there a treatment for aphasia? Or, if someone is diagnosed with it, how can they manage the ailment?

This again depends somewhat on the underlying cause. If an underlying cause can be identified, such as a tumor or infection, treatment of the cause may improve symptoms. If due to a stroke or traumatic injury where the lesion is static or non-progressive, speech and language therapy can provide improvements or, at the very least, coping strategies. In the case of neurodegenerative disease, there are few clearly effective options, although some individuals may benefit for a short time from speech therapy. As swallowing difficulties can sometimes accompany language difficulties, it is important to rule this out so to avoid aspiration pneumonia.

What is the difference between simple forgetfulness and symptoms that indicate there is something more serious happeninglike aphasia, dementia, or Alzheimers?

Memory loss is not a part of the normal aging process, although many older adults subjectively report their memory is not as good as it once was. Instead of being truly forgetful, processing speed declines so that it takes longer than usual to recall information. But with time, the information is recalled, and people can benefit from clues or prompts. Progressive changes in memory, language, or other cognitive functions are often a sign of a neurodegenerative disease such as Alzheimers disease or a related dementia such as primary progressive aphasia, frontotemporal degeneration, or Lewy body dementia. Difficulty finding the right words can be an early sign of all of these conditions.

What is the difference between aphasia and dysphasia?

Aphasia is the loss of language, while dysphasia means impaired language. Neurologists often dont use the term dysphasia because it can be confused with dysphagia which means difficulty swallowing.

More here:
Neurology specialist addresses aphasia, the illness affecting Bruce Willis - University of Miami: News@theU

Doctors say heavy Tik-Tok usage is causing neurological health complications – WPMT FOX 43

The medical professionals say these teens are developing tics after watching videos of those with Tourette's Syndrome.

HARRISBURG, Pa. With its popularity growing since its launch in the U.S. in 2018, Tik-Tok has become a sensation for its users promoting creativity and entertainment.

Doctors across the globe say they are seeing complications in movement from teenage girls as a greater number are seeking treatment for tics. They say the young teens are developing the tics after watching Tik-Tok videos of creators who have Tourette's syndrome.

One might ask, what is the difference?

"A tic is a complicated movement that's stored in the center part of the brain that you feel this pressure that pushes movement out and you can try to hold it back but it gets stronger and stronger often when you do until it forces it's way out," said Dr. Jeremy Timothy, a pediatric neurologist for WellSpan Health.

Timothy says Tourette's syndrome, on the other hand, is a type of tic disorder, where people have multiple tics persistently over a course of time. This type of disorder usually arises in children, but Timothy says he's seen cases in teens now.

Research has pointed out teen girls who developed these tics during the pandemic had pre-existing mental health issues making them prone to other disorders.

Dr. Melissa Brown, a psychologist for UPMC, says stress and anxiety toppled by the pandemic are a "perfect storm" to create issues like these.

"The pandemic hit, placing a lot of social constraints on our teens, and girls tend to be very social and integrated into their social circles," she said.

Timothy says it's important for parents to speak to their children's doctors and if they happened to have tics, seek out treatments. Some of these include medications or CBIT -- Comprehensive Behavioral Intervention for Tics.

This is a therapy where one learns tricks to substitute different movements for tics that is less noticeable or shift gears in your mind from something that may trigger tics.

Another way for parents to help is to be more engaged and present in their child's life.

"Engaging in conversations, getting more physical activity, making sure they're sleeping well-our teens do need a lot of sleep," said Brown. "Of course, watch their diets and checking out what they're consuming."

Tik-Tok has responded to the issue publically, stating people with Tourette's Syndrome use the app "to express themselves authentically, find community and fight stigma."

More:
Doctors say heavy Tik-Tok usage is causing neurological health complications - WPMT FOX 43

Preliminary Study: Drug May Be Safe in Those with Mild Cognitive Impairment, Mild Dementia – Newswise

EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, THURSDAY, MARCH 31, 2022

Newswise MINNEAPOLIS A small, preliminary study of an investigational new drug being studied for mild cognitive impairment and mild dementia associated with Alzheimers disease suggests it is safe and may be associated with improvements in executive function, thinking and memory skills. The study is released today, March 31, 2022, and will be presented at the American Academy of Neurologys 74th Annual Meeting being held in person in Seattle, April 2 to 7, 2022 and virtually, April 24 to 26, 2022. The drug, called SAGE-718, is also in clinical trials for the treatment of cognitive impairment associated with Parkinsons disease and Huntingtons disease.

Cognitive impairment is often one of the earliest signs of Alzheimers disease, can be very difficult for patients and their families, and represents an area of great unmet medical need, said study author Aaron Koenig, MD, of Sage Therapeutics in Cambridge, Mass., the maker of the investigational drug. These results support further research with larger numbers of people to determine whether this therapy is safe and effective in treating cognitive impairment in Alzheimers disease and related disorders and in improving how well people can function independently in their everyday lives.

The study involved 26 people with an average age of 67. They had an average score of 20.7 points on a common cognitive test, indicating cognitive performance consistent with mild cognitive impairment or mild dementia. The participants took SAGE-718 daily for two weeks and were then followed for another two weeks. They completed tests of thinking and memory at the beginning of the study, at the end of treatment, and after one month. Both the participants and researchers knew that SAGE-718 was being administered.

The study was designed mainly to gather data on the drugs safety. There were no serious side effects of the drug. Five people had mild or moderate side effects believed to be related to the drug, such as headache or constipation.

After one month, the participants scores on the cognitive test had improved by an average of 2.3 points, to 22.8 points.

Koenig said some participants also had improvement in assessments of how well they were able to complete their daily activities, especially in complex activities such as using a computer, carrying out household chores, and managing their medications. This coincided with consistent improvement on multiple tests of executive functioning that were administered during the trial.

Koenig said, If replicated in future studies, such improvements suggest that this drug may eventually provide meaningful benefits to people in their everyday lives.

SAGE-718 is a type of drug called a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors.

The studys limitations include its small size and that participants and researchers knew that the drug was being administered, which could lead to bias.

The study was supported by Sage Therapeutics, Inc.

Learn more about brain health at BrainandLife.org, home of the American Academy of Neurologys free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

When posting to social media channels about this research, we encourage you to use the American Academy of Neurologys Annual Meeting hashtag #AANAM.

The American Academy of Neurology is the worlds largest association of neurologists and neuroscience professionals, with over 38,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimers disease, stroke, migraine, multiple sclerosis, concussion, Parkinsons disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

More here:
Preliminary Study: Drug May Be Safe in Those with Mild Cognitive Impairment, Mild Dementia - Newswise

Horizon Therapeutics Highlights Presentation During Poster Presentation At American Academy Of Neurology On Co.’s UPLIZNA – Benzinga

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. Youll have what you need to act in real-time before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more from the original source:
Horizon Therapeutics Highlights Presentation During Poster Presentation At American Academy Of Neurology On Co.'s UPLIZNA - Benzinga

Innovative therapy reverses neuropathology in elderly woman | Duke Department of Neurology – Duke Department of Neurology

A female in her 70s experienced weakness in her legs, trouble swallowing, and several falls. When she fell and couldnt get up, she called an ambulance and was transported to a local hospital.

Physicians at the hospital consulted Duke Healths neurology experts, who suggested a diagnosis of Guillain-Barre syndrome. The local hospital initiated a standard treatment for Guillain Barreintravenous immunoglobulin (IVIG)but the patient did not respond after two treatments. Because of a rapid deterioration of muscular function, she was transferred to Duke Hospital overnight. The deterioration ascended from her feet and began to compromise her pharyngeal and respiratory muscles.

When I arrived at the hospital, she was decompensating quickly. She was taken to the neurological ICU where she was intubated and placed on a ventilator, says Jordan L. Mayberry, MD, a neuromuscular specialist on duty that day. Mayberry was concerned by her lack of response to IVIG. To head off any further deterioration, he made the fast decision to change to a treatment the local hospital did not offer.

What therapy offered at Duke but few other North Carolina hospitals did Mayberry institute for a better chance at speeding the patients recovery?

Read more here:
Innovative therapy reverses neuropathology in elderly woman | Duke Department of Neurology - Duke Department of Neurology

Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology…

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced they will give one oral presentation and present one poster at the 2022 American Academy of Neurology Annual Meeting, taking place on April 2-7, 2022 in Seattle, Washington.

We look forward to participating at AAN this year, where we will give our first, in-person oral presentation of the ASPEN-1 Phase 3 clinical trial results, and also present new data from the ASPEN-OLS Phase 3 open-label, long-term safety study of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia, said Mark J. Foley, Chief Executive Officer of Revance. As we seek to help patients with this debilitating condition achieve long-lasting symptom relief, the important data from our ASPEN-1 Phase 3 program continues to show DaxibotulinumtoxinA for Injections long duration of effect and encouraging safety profile. The pivotal ASPEN-1 trial demonstrated two efficacious and well-tolerated dose levels of DaxibotulinumtoxinA for Injection compared to placebo, with consistent patient and clinician reports of improvement and treatment satisfaction. Results from the ASPEN-OLS study reinforce the long-term safety and efficacy of our pivotal study with up to four repeat doses.

Oral Presentation:

Poster:

The above abstracts are available online via the AAN website at http://www.aan.com.

About Revance

Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX, which if approved, would be the first and only generic biosimilar to Botox and Botox Cosmetic. For more information or to join our team visit us at http://www.revance.com.

Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

BOTOX is a registered trademark of Allergan, Inc.

Forward-Looking Statements

Any statements in this press release that are not statements of historical fact, including statements related to the potential benefits, efficacy and duration of DaxibotulinumtoxinA for Injection and our development of a biosimilar to BOTOX with our partner, Viatris, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: the results, timing, costs, and completion of our research and development activities and regulatory approvals; our ability to remediate deficiencies identified by the FDA and obtain FDA approval of the BLA for DaxibotulinumtoxinA for Injection for glabellar lines, including as a result of observations made by the FDA during the site inspection or other reasons; our ability to obtain funding for our operations; the timing of capital expenditures; the accuracy of our estimates regarding expenses, future revenues, capital requirements, our financial performance and the economics of DaxibotulinumtoxinA for Injection, the RHA Collection of dermal fillers and OPUL; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end user demand for our products and services, the aesthetics market, commercialization efforts, business operations, regulatory meetings, inspections and approvals, clinical trials and other aspects of our business and on the market; our ability and the ability of our partners to manufacture supplies for our product candidates and to acquire supplies of the RHA Collection of dermal fillers; the uncertain clinical development process, the risk that clinical trials may not have an effective design or generate positive results or that positive results would assure regulatory approval or commercial success; the applicability of clinical study results to actual outcomes; the rate and degree of economic benefit, safety, efficacy, commercial acceptance, market, competition and/or size and growth potential of the RHA Collection of dermal fillers, OPUL and our drug product candidates, if approved; our ability to continue to successfully commercialize the RHA Collection of dermal fillers and OPUL and our ability to successfully commercialize DaxibotulinumtoxinA for Injection, if approved, and the timing and cost of commercialization activities; the proper training and administration of our products by physicians and medical staff; our ability to expand sales and marketing capabilities; the status of commercial collaborations; changes in and failures to comply with privacy and data protection laws; our ability to effectively manage our expanded operations in connection with the acquisition of Hint, Inc; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; the cost and our ability to defend ourselves in product liability, intellectual property, class action or other lawsuits; the volatility of our stock price; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risks Factors" in our Form 10-K, filed with the SEC on February 28, 2022. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Read more from the original source:
Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology...

Global In-Vitro Diagnostics For Cardiology And Neurology Market Driving Factors, Industry Growth, And Forecast To 2031 ChattTenn Sports – ChattTenn…

Research Nester published a report titled In-Vitro Diagnostics for Cardiology and Neurology Market: Global Demand Analysis & Opportunity Outlook 2031 which delivers detailed overview of the global in-vitro diagnostics for cardiology and neurology market in terms of market segmentation by product type, technology, end user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

Theglobal in-vitro diagnostics for cardiology and neurology marketis estimated to occupy a sizeable revenue by growing at a CAGR of ~6% during the forecast period, i.e., 2022 2031, ascribing to the rising adoption of point-of-care testing devices to boost the demand for in-vitro diagnostics tests. Along with this, growing prevalence of chronic disorders across the globe, and escalating awareness levels associated with disease diagnosis, and rapidly increasing geriatric population are also expected to accelerate the growth of the market in the upcoming years.

The market is segmented by product type, technology and end user. Based on type, the reagents & consumables segment is anticipated to acquire the largest share during the forecast period on the back of the high precision and accurate diagnosis provided by recently developed reagents & consumables. Additionally, by end user, the hospitals segment is projected to grab the largest share over the forecast period attributing to the tremendous amount of diagnostic testing required to support a clinical decision for enhancing patient discovery, which is only possible in a hospital facility.

For More Information About This Report Visit:https://www.researchnester.com/sample-request-3849

Geographically, the global in-vitro diagnostics for cardiology and neurology market is segmented into five major regions, namely North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. Asia Pacific is evaluated to witness noteworthy growth in the market during the forecast period. This can be attributed to the rising investments by healthcare providers for improving the diagnostics infrastructure in the region. Moreover, the market in North America is assessed to acquire the largest share over the forecast period ascribing to the high healthcare spending, and strong presence of market players in the region.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Growing Occurrence of Chronic Disorders Around the World to Bolster Market Growth

Since the last few years, the prevalence of several cardiovascular and neurological diseases is increasing significantly. This is resulting in the rise in awareness regarding early diagnosis among the population and an increase in routine diagnosis, which in turn is anticipated to boost the demand for advanced in-vitro diagnostics products in the near future.

However, the expensiveness of in-vitro diagnostics instruments is expected to operate as key restraint to the growth of the global in-vitro diagnostics for cardiology and neurology market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global in-vitro diagnostics for cardiology and neurology market which includes company profiling of Thermo Fisher Scientific Inc., F. Hoffman-La Roche Ltd, Sysmex Corporation, Siemens AG, Becton, Dickinson, and Company, DiaSorin S.p.A., Quest Diagnostics, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, Danaher Corporation, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global in-vitro diagnostics for cardiology and neurology market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Get a Sample Copy Of This Report With Graphs and Charts:https://www.researchnester.com/sample-request-3849

Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.

For more information, please contact:

AJ Daniel

Research NesterEmail: [emailprotected]Tel: +1-6465869123

Related Links

Animal Healthcare MarketWriting Instruments MarketSupercapacitor MarketIndustrial Salt MarketAutomotive Lightweight Material MarketDrug (Medicine) Dispenser MarketOffice Furniture MarketPC Accessories MarketU.S. 3D Printing Market3D Printed Medical Device Market

Read the original:
Global In-Vitro Diagnostics For Cardiology And Neurology Market Driving Factors, Industry Growth, And Forecast To 2031 ChattTenn Sports - ChattTenn...

Sigyn Therapeutics Appoints Ajay Verma, MD, Ph.D. to its Scientific Advisory Board – GlobeNewswire

SAN DIEGO, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:SIGY), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis and other life-threatening disorders, today announced the appointment of Ajay Verma, M.D., Ph.D.to its Scientific Advisory Board.

Dr. Verma is a recognized thought leader in the field of neurology. His extensive clinical experience and resulting insights are anticipated to contribute to the continued advancement of Sigyn Therapy. Sigyn Therapy is an extracorporeal blood purification technology being advanced to treat life-threatening inflammatory disorders.

Dr. Verma is a neurologist, neuroscientist, drug developer, inventor, and biotech science advisor. Dr. Verma most recently headed R&D efforts at Yumanity Therapeutics, developing drugs against novel targets for treating neurodegenerative diseases. Prior to that he was the EVP of Research and Experimental Medicine at Codiak Biosciences. He has also served as CMO at United Neuroscience (now called Vaxxinity), VP of Neurology at Biogen and Novartis, and Director of Neuroscience Experimental Medicine at Merck. His drug development experience spans small molecule, peptide/protein, antibody, oligonucleotide, vaccine, and exosome drug platforms. He has largely focused on translational and early clinical development in neurology indications using precision drug development approaches that leverage biomarkers and experimental medicine paradigms. Prior to his Biopharma career, Dr. Verma was Professor of Neurology at the Uniformed Services University of the Health Sciences. He also worked as a staff neurologist at the Walter Reed Army Medical Center for 11 years after completing his neurology residency there. He received his M.D. and Ph.D. from Johns Hopkins University, where he trained in the laboratory of Dr. Solomon Snyder. He received his B.S. in Zoology from the University of Maryland.

About Sigyn Therapeutics

Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide. Sigyn Therapy is a multi-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream.

Beyond establishing a novel strategy to combat sepsis, candidate treatment indications for Sigyn Therapy include, but are not limited to; emerging pandemic threats, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP), which is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases.

To learn more, visit http://www.SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Stephen Kilmer

Sigyn Therapeutics, Inc.

Investor Relations

(646) 274-3580

stephen@sigyntherapeutics.com

Media Contacts:

Russo Partners, LLC

David Schull

(212) 845-4271

David.Schull@russopartnersllc.com

Nic Johnson

(212) 845-4242

Nic.Johnson@russopartnersllc.com

Go here to read the rest:
Sigyn Therapeutics Appoints Ajay Verma, MD, Ph.D. to its Scientific Advisory Board - GlobeNewswire

Vladimir Putin – Ex-Wife, Age & Facts – Biography

Vladimir Putin served as president of Russia from 2000 to 2008 and was re-elected to the presidency in 2012. He previously served as Russia's prime minister.

In 1999, Russian president Boris Yeltsin dismissed his prime minister and promoted former KGB officer Vladimir Putin in his place. In December 1999, Yeltsin resigned, appointing Putin president, and he was re-elected in 2004. In April 2005, he made a historic visit to Israel the first visit there by any Kremlin leader. Putin could not run for the presidency again in 2008, but was appointed prime minister by his successor, Dmitry Medvedev. Putin was re-elected to the presidency in March 2012 and later won a fourth term. In 2014, he was reportedly nominated for a Nobel Peace Prize.

Vladimir Vladimirovich Putin was born in Leningrad (now St. Petersburg), Russia, on October 7, 1952. He grew up with his family in a communal apartment, attending the local grammar and high schools, where he developed an interest in sports. After graduating from Leningrad State University with a law degree in 1975, Putin began his career in the KGB as an intelligence officer. Stationed mainly in East Germany, he held that position until 1990, retiring with the rank of lieutenant colonel.

Upon returning to Russia, Putin held an administrative position at the University of Leningrad, and after the fall of communism in 1991 became an adviser to liberal politician Anatoly Sobchak. When Sobchak was elected mayor of Leningrad later that year, Putin became his head of external relations, and by 1994, Putin had become Sobchak's first deputy mayor.

After Sobchak's defeat in 1996, Putin resigned his post and moved to Moscow. There, in 1998, Putin was appointed deputy head of management under Boris Yeltsin's presidential administration. In that position, he was in charge of the Kremlin's relations with the regional governments.

Shortly afterward, Putin was appointed head of the Federal Security Service, an arm of the former KGB, as well as head of Yeltsin's Security Council. In August 1999, Yeltsin dismissed his prime minister, Sergey Stapashin, along with his cabinet, and promoted Putin in his place.

In December 1999, Boris Yeltsin resigned as president of Russia and appointed Putin acting president until official elections were held, and in March 2000, Putin was elected to his first term with 53 percent of the vote. Promising both political and economic reforms, Putin set about restructuring the government and launching criminal investigations into the business dealings of high-profile Russian citizens. He also continued Russia's military campaign in Chechnya.

In September 2001, in response to the terrorist attacks on the United States, Putin announced Russia's support for the United States in its anti-terror campaign. However, when the United States' "war on terror" shifted focus to the ousting of Iraqi leader Saddam Hussein, Putin joined German Chancellor Gerhard Schrder and French President Jacques Chirac in opposition of the plan.

In 2004, Putin was re-elected to the presidency, and in April of the following year made a historic visit to Israel for talks with Prime Minister Ariel Sharon marking the first visit to Israel by any Kremlin leader.

Due to constitutional term limits, Putin was prevented from running for the presidency in 2008. (That same year, presidential terms in Russia were extended from four to six years.) However, when his protg Dmitry Medvedev succeeded him as president in March 2008, he immediately appointed Putin as Russia's prime minister, allowing Putin to maintain a primary position of influence for the next four years.

On March 4, 2012, Vladimir Putin was re-elected to his third term as president. After widespread protests and allegations of electoral fraud, he was inaugurated on May 7, 2012, and shortly after taking office appointed Medvedev as prime minister. Once more at the helm, Putin has continued to make controversial changes to Russia's domestic affairs and foreign policy.

In December 2012, Putin signed into a law a ban on the U.S. adoption of Russian children. According to Putin, the legislationwhich took effect on January 1, 2013 aimed to make it easier for Russians to adopt native orphans. However, the adoption ban spurred international controversy, reportedly leaving nearly 50 Russian children who were in the final phases of adoption with U.S. citizens at the time that Putin signed the law in legal limbo.

Putin further strained relations with the United States the following year when he granted asylum to Edward Snowden, whois wanted by the United States for leaking classified information from the National Security Agency. In response to Putin's actions,U.S. President Barack Obamacanceled a planned meeting with Putin that August.

Around this time, Putin also upset many people with his new anti-gay laws. He made it illegal for gay couples to adopt in Russia and placed a ban on propagandizing "nontraditional" sexual relationships to minors. The legislation led to widespread international protest.

In September 2013, tensions rose between the United States and Syria over Syria's possession of chemical weapons, with the U.S. threatening military action if the weapons were not relinquished. The immediate crisis was averted, however, when the Russian and U.S. governments brokered a deal whereby those weapons would be destroyed.

On September 11, 2013, The New York Times publishedan op-ed piece by Putin titled "A Plea for Caution From Russia." In the article, Putin spoke directly to the U.S.'s position in taking action against Syria, stating that such a unilateral move could result in the escalation of violence and unrest in the Middle East.

Putin further asserted that the U.S. claim that Bashar al-Assad used the chemical weapons on civilians might be misplaced, with the more likely explanation being the unauthorized use of the weapons by Syrian rebels. He closed the piece by welcoming the continuation of an open dialogue between the involved nations to avoid further conflict in the region.

In 2014, Russia hosted the Winter Olympics, which were held in Sochi beginning on February 6. According to NBS Sports, Russia spent roughly $50 billion in preparation for the international event.

However, in response to what many perceived as Russia's recently passed anti-gay legislation, the threat of international boycotts arose. In October 2013, Putin tried to allay some of these concerns, saying in an interview broadcast on Russian television that "We will do everything to make sure that athletes, fans and guests feel comfortable at the Olympic Games regardless of their ethnicity, race or sexual orientation."

In terms of security for the event, Putin implemented new measures aimed at cracking down on Muslim extremists, and in November 2013 reports surfaced that saliva samples had been collected from some Muslim women in the North Caucasus region. The samples were ostensibly to be used to gather DNA profiles, in an effort to combat female suicide bombers known as "black widows."

Shortly after the conclusion of the 2014 Winter Olympics, amidst widespread political unrest in Ukraine, which resulted in the ousting of President Viktor Yanukovych, Putin sent Russian troops into Crimea, a peninsula in the country's northeast coast of the Black Sea. The peninsula had been part of Russia until Nikita Khrushchev, former Premier of the Soviet Union, gave it to Ukraine in 1954.

Ukraine's ambassador to the United Nations, Yuriy Sergeyev, claimed that approximately 16,000 troops invaded the territory, and Russia's actions caught the attention of several European countries and the United States, who refused to accept the legitimacy of a referendum in which the majority of the Crimean population voted to secede from Ukraine and reunite with Russia.

Putin defended his actions, insisting that the troops sent into Ukraine were only meant to enhance Russia's military defenses within the country referring to Russia's Black Sea Fleet, which has its headquarters in Crimea. He also vehemently denied accusations by other nations, particularly the United States, that Russia intended to engage Ukraine in war.

He went on to claim that although he was granted permission from Russia's upper house of Parliament to use force in Ukraine, he found it unnecessary. Putin also wrote off any speculation that there would be a further incursion into Ukrainian territory, saying, "Such a measure would certainly be the very last resort."

The following day, it was announced that Putin had been nominated for the 2014 Nobel Peace Prize.

In September 2015, Russia surprised the world by announcing it would begin strategic airstrikes in Syria. Despite government officials' assertions that the military actions were intended to target the extremist Islamic State, which made significant advances in the region due to the power vacuum created by Syria's ongoing civil war, Russia's true motives were called into question, with many international analysts and government officials claiming that the airstrikes were in fact aimed at the rebel forces attempting to overthrow President Bashar al-Assad's historically repressive regime.

In late October 2017, Putin was personally involved in another alarming form of aerial warfare when he oversaw a late-night military drill that resulted in the launch of four ballistic missiles across the country. The drill came during a period of escalating tensions in the region, with Russian neighbor North Korea also drawing attention for its missile tests and threats to engage the U.S. in destructive conflict.

In December 2017, Putin announced he was ordering Russian forces to begin withdrawing from Syria, saying the country's two-year campaign to destroy ISIS was complete, though he left open the possibility of returning if terrorist violence resumed in the area. Despite the declaration, Pentagon spokesmanRobert Manning was hesitantto endorse that view of events, saying,"Russian comments about removal of their forces do not often correspond with actual troop reductions."

Months prior to the 2016 U.S. presidential election, multiple U.S. intelligence agencies unilaterally agreed that Russian intelligence was behind the email hacks of the Democratic National Committee (DNC) and John Podesta,who had, at the time, been chairman of Democratic presidential candidate Hillary Clinton's campaign.

In December 2016 unnamed senior CIA officials further concluded "with a high level of confidence" that Putin was personally involved in intervening in the U.S. presidential election, according to a report byUSA Today. The officials further went on to assert that the hacked DNC and Podesta emailsthat were given to WikiLeaks just before U.S. Election Day were designed to undermine Clinton's campaignin favor of her Republican opponent, Donald Trump. Soon after, the FBI and National Intelligence Agency publicly supported the CIA's assessments.

Putin denied any such attempts to disrupt the U.S. election, and despite the assessments of his intelligence agencies, President Trump generally seemed to favor the word of his Russian counterpart. Underscoring their attempts to thaw public relations, the Kremlin in late 2017 revealed that a terror attack had been thwarted in St. Petersburg, thanks tointelligence provided by the CIA.

Around that time,Putin reported at his annual end-of-year press conference that he would seek a new six-year term as president in early 2018 as an independent candidate, signaling he was ending his longtime association with the United Russia party.

Shortly before the first formal summit between Presidents Putin and Trump in July 2018, the U.S. Department of Justice announced the indictments of 12 Russian operatives on charges relating to interference in the 2016 U.S. presidential election. Regardless, Trump suggested he was satisfied with his counterpart's "strong and powerful" denial in a joint news conference and praised Putin's offer to submit the 12 indicted agents to questioning with American witnesses present.

In a subsequent interview with Fox News anchor Chris Wallace, Putin seemingly defended the hacking of the DNC server by suggesting that no false information was planted in the process. He also rejected the idea that he had compromising information about Trump, saying that the businessman "was of no interest for us" before announcing his presidential campaign, and notably refused to touch a copy of the indictments offered to him by Wallace.

In March 2018, toward the end of his third term, Putin boasted of new weaponry that would render NATO defenses "completely worthless," including a low-flying nuclear-capable cruise missile with "unlimited" range and another one capable of traveling at hypersonic speed. His demonstration included video animation of attacks on the United States.

Not long afterward, a two-hour documentary, titled Putin, was posted to several social media pages and a pro-Kremlin YouTube account. Designed to showcase the president in a strong yet humane light, the doc featured Putin sharing the story of how he ordered a hijacked plane shot down to head off a bomb scare at the 2014 Sochi Olympics, as well as recollections of his grandfather's days as a cook for Vladimir Lenin and Joseph Stalin.

On March 18, 2018, the fourth anniversary of the country's seizure of Crimea, Russian citizens overwhelmingly elected Putin to a fourth presidential term, with 67 percent of the electorate turning out to award him more than 76 percent of the vote. The divided opposition stood little chance against the popular leader, his closest competitor notching around 13 percent of the vote.

Little was expected to change regarding Putin's strategies for rebuilding the country as a global power, though the start of his final term set off questions about his successor, and whether he would affect constitutional change in an attempt to remain in office indefinitely.

On July 16, 2018, Putin met with President Trump in Helsinki, Finland, for the first formal talks between the two leaders. According to Russia, topics of the meeting included the ongoing war in Syria and "the removal of the concerns" about accusations of Russian attempts to influence the 2016 U.S. presidential election.

The following April, Putin met with North Korean dictator Kim Jong-un for the first time. The two leaders discussed the issue of the North Korean laborers in Russia, while Putin also offered support of his counterpart's denuclearization negotiations with the U.S., saying Kim would need "security guarantees" in exchange for abandoning his nuclear program.

The topic of whether Putin aimed to extend his hold on power resurfaced following hisstate-of-the-nation speech in January 2020, which included proposals for constitutional amendments that included transferring the power to select the prime minister and cabinet from the president to the Parliament. The entire cabinet, including Medvedev, promptly resigned, leading to the selection of Mikhail V. Mishustin as the new prime minister.

In 1980, Putin met his future wife, Lyudmila, who was working as a flight attendant at the time. The couple married in 1983 and had two daughters: Maria, born in 1985, and Yekaterina, born in 1986. In early June 2013, after nearly 30 years of marriage, Russia's first couple announced that they were getting a divorce, providing little explanation for the decision, but assuring that they came to it mutually and amicably.

"There are people who just cannot put up with it," Putin stated. "Lyudmila Alexandrovna has stood watch for eight, almost nine years." Providing more context to the decision, Lyudmila added, "Our marriage is over because we hardly ever see each other. Vladimir Vladimirovich is immersed in his work, our children have grown and are living their own lives."

An Orthodox Christian, Putin is said to attend church services on important dates and holidays on a regular basis and has had a long history of encouraging the construction and restoration of thousands of churches in the region. He generally aims to unify all faiths underthe government's authorityand legally requires religious organizations to register with local officials for approval.

Watch "Vladimir Putin" on HISTORY Vault

Visit link:

Vladimir Putin - Ex-Wife, Age & Facts - Biography

Putin’s only real vulnerability the Russian street | TheHill

Landmarks around the world, from Berlins Brandenburg Gate to Romes Colosseum and Londons 10 Downing Street, have been lit with the colors of the Ukrainian flag to show support for Ukraine after Russias invasion. In nearly every major city, thousands of people have amassed in public squares and outside Russian embassies in protest. In Bucharest, the crowds chanted, Putin the assassin. In Geneva, one native Russian told the media, Im ashamed of my country of birth.

But, most importantly, the Russian people inside Russia are protesting. Dozens of Russian celebrities have already spoken out against the invasion. One online petition gathered nearly a million signatures in four days, and anti-war rallies have taken place in at least 51 cities around the country, including at Great Gostiny Dvor, one of St. Petersburgs most famous landmarks.

Right now, Russians are torn over Russian President Vladimir PutinVladimir Vladimirovich PutinUS set to sanction more Russian oligarchs: report Biden hails UN vote: 'Lays bare Putin's isolation' Substitute teacher suspended for remarks supporting Putin's invasion of Ukraine MOREs invasion of Ukraine. On one hand, Putin is telling them it is a necessary action to prevent hostilities against our country. But as images of the atrocities come out a fatally wounded child in unicorn pajamas; a mother delivering a baby in a bomb shelter Putins grip on the narrative is faltering.

Heres why this matters: Putin requires public support. He can survive in power with economic sanctions targeting his inner circle, his major industries and his country. He can survive an onslaught of foreign weapons and forces sent to Ukraine and his military planes shot down. But he absolutely cannot survive the loss of the Russian streets. He must maintain popular support.

Ive spent my career studying violence, and the pattern is always the same: A political leader gains support by marketing violence as essential to his groups well-being. As Soviet dissident Aleksandr Solzhenitsyn once said, Ideology that is what gives evil doing its long-sought justification.

Putin has never shied away from praising Stalin and his ideology. But it begs the question: Could Stalin and his Gulags and his torture chambers and his massacres have happened today, in the internet era?

Warfare politics is really just a game of marketing and branding. Nothing is more important to the success of a violent campaign than the narrative behind it. Osama bin Laden grounded his narrative in religion. In his 2002 letter to the American people (which was really a letter intended to inspire his own followers), he began by quoting the Quran: So fight you against the friends of Satan.

Maos Cultural Revolution seems similar to todays moves by Putin. Mao invoked the narrative of class struggle to justify his violence: If the peasants do not apply great force, the power of the landlords, built up over thousands of years, can never be uprooted.

Putins narrative is an ideology of nationalism. In his Feb. 21 speech, he constructed a narrative, mainly directed toward his own people, that his invasion is intended to protect what is rightfully Russian, to prevent the disintegration of our united country. Modern Ukraine, he wrongly asserted, was entirely created by Russia and is an inalienable part of our own history, culture and spiritual space.

He also used a classic strategy for building support for violence setting up a framework of us versus them. They are torturing people, children, women, elderly people, he said of Ukrainian forces. And the only goal they [Western leaders] have is to contain the development of Russia. It does not matter to the success of his campaign that these accusations are entirely false. All that matters is, as The New York Times says, at least muddying the Russian publics understanding. Every prominent invader in history, from Stalin to Hitler to ISIS leaders, have relied on this same strategy.

If Stalin could not succeed in the internet era, then Putin will fail. Millions of people assembled in the streets of Egypt in 2011, backed by a world watching online, overpowered Egypts long-serving president Hosni Mubarak. The voices of the people, when amplified, can overpower even the strongest leader.

President BidenJoe BidenBiden hails UN vote: 'Lays bare Putin's isolation' Overnight Defense & National Security US tries to turn down the dial on Russia Johns Hopkins doctor says children need to get vaccinated against COVID-19 MORE, other heads of state, members of Congress and freely elected legislators around the world, celebrities and social media influencers, and all people of the world must engage in the counter-narrative. Praise the people of Ukraine for their courage and share in their pain. But most importantly, to reverse this ill-conceived invasion and end the suffering and madness, support the people protesting in the Russian street, because only they can overpower Putin.

Gary M.Shiffman, Ph.D., is an economist, a Gulf War veteran and a former chief of staff of U.S. Customs and Border Protection. He is the founder ofGiant OakandConsilientand author of The Economics of Violence: How Behavioral Science Can Transform our View of Crime, Insurgency, and Terrorism.

Read more here:

Putin's only real vulnerability the Russian street | TheHill